The Importance of Research on Rare Subtypes of Melanoma
March 28th 2018Jason J. Luke, MD, assistant professor of medicine at the The University of Chicago Medicine, discusses the importance of conducting research into less common subsets of melanoma. After giving a talk on non-cutaneous melanoma, a rare subtype, Luke explained that not all cases of melanoma arise on the skin and shared why more research is necessary in the field.
Watch
An Overview of Vigil Personalized Engineered Autologous Tumor Cells in Ovarian Cancer
March 27th 2018Rodney P. Rocconi, MD, chief of Gynecologic Oncology Service, associate director for Clinical Research, professor of Interdisciplinary Clinical Oncology, discusses a phase I trial of Vigil personalized engineered autologous tumor cells in ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
Watch
Efficacy Results for Trastuzumab in HER2-Positive Uterine Serous Carcinoma
March 27th 2018Alessandro D. Santin, MD, a professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses results of a randomized phase II trial of trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab (Herceptin) in advanced or recurrent uterine serous carcinomas that overexpress HER2/neu during the 2018 Society of Gynecologic Oncology Annual Meeting.
Watch
Approaches for Transitioning to Multidisciplinary Cancer Care Teams
March 26th 2018Mark S. Soberman, MD, MBA, FACS, 2017-2018 president of the Association of Community Cancer Centers (ACCC), discusses various approaches that can be used to integrate multidisciplinary healthcare programs into various healthcare settings, following a panel discussion during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
Watch
Predicting Response to PARP Inhibitor Therapy in Ovarian Cancer
March 25th 2018Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.
Watch
Future Treatment Options for Patients With RCC
March 23rd 2018Hans Hammers, MD, PhD, associate professor at the University of Texas Southwestern Medical Center, discusses what he believes is most important in future investigation for the treatment of patients with renal cell carcinoma. With combination therapies on the rise in the field of kidney cancers, new pivotal and early clinical trials are constantly arising looking at new combination regimens.
Watch
Long-term Results of Zuma-1 Trial for Patients with NHL
March 23rd 2018Frederick Locke, MD, co-leader of the Department of Blood and Marrow Transplant and Cellular Immunotherapy Program at Moffitt Cancer Center, discussed the long-term follow-up results of the pivotal ZUMA-1 trial. These updated findings were presented at the 2017 ASH Annual Meeting, showing promise in the treatment of patients with non-Hodgkin lymphoma.
Watch
The Significance of Brain Metastases in Non-Small Cell Lung Cancer
March 21st 2018Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer.
Watch
Current Research on Identifying Biomarkers in Breast Cancer
March 21st 2018Elizabeth Mittendorf, MD, PhD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the importance of identifying biomarkers in patients with breast cancer. Current studies are looking at PD-L1 as a possible biomarker, but Mittendorf believes there may be other biomarkers that will prove to be more reliable.
Watch